

Consideration for the Initiation of Tocilizumab in COVID-19

Note: Please contact clinical pharmacist prior to verifying tocilizumab during day shift. For nights/weekends, the following criteria may be utilized

Based on the preliminary results of the REMAP-CAP and RECOVERY trial, tocilizumab is conditionally recommended in conjunction with steroids per the IDSA guidelines for the treatment of COVID-19. Tocilizumab should be carefully considered given the risks of secondary infections associated with its use. In an effort to standardize delivery and receipt of the medication within FMOLHS hospitals, a proposed criterion for use and administration of the medication has been created.

I.

Inclusion (must meet the following)	Cautions
Admitted ≥18 years	Prior receipt of tocilizumab or known hypersensitivity
Positive COVID Test	Immunocompromised state
Receiving corticosteroids	Platelet count <50K
CRP ≥ 7.5mg/dL (75mg/L)	AST/ALT >5x ULN

II. Dosing Recommendations:

- Tocilizumab **8mg/kg** (total body weight; max **800mg**) as a **one time dose**
 - Doses will be rounded to the nearest 100mg
 - Dose will be diluted in 100mL NS and infused over 1 hour
- Tocilizumab should not be infused in the same IV line with concomitant medications

III. Other considerations

- After tocilizumab is administered, there is little data to suggest the use of remdesivir.
- There is no data to suggest the use of remdesivir and baricitinib after use of tocilizumab.